The Latest Cardiac and Vascular News
AstraZeneca Direct is designed to offer greater convenience WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca today announces the launch of AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access their prescribed medications at a transparent cash price with home delivery. AstraZeneca Direct will support people living […]
Funding supports clinical trials of a minimally invasive therapy targeting a root cause of heart failure; co-founder Zoar Engelman, PhD, appointed CEO NEW YORK, Sept. 25, 2025 /PRNewswire/ — Axon Therapies, a clinical-stage medical device company pioneering a new approach to treating…
Data to be presented include two subgroup analyses from the pivotal Phase III FINEARTS-HF trial, which assessed the safety and efficacy of finerenone versus placebo in heart failure (HF) patients with left ventricular ejection fraction (LVEF) ≥40%. These analyses explored potential treatment effects in patients across a range of heart […]
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has entered a national partnership in the USA with Optum Healthcare. The inclusion of Philips’ Mobile Cardiac Telemetry (MCOT) and Philips Extended Holter (ePatch) in the network is designed to enable earlier detection of […]
By targeting the underlying drivers of disease with a pipeline of complementary candidates, Kardigan is building a platform that accelerates insights into core cardiovascular pathways to address multiple conditions where no treatments exist SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.–(BUSINESS WIRE)–Kardigan, a heart health company modernizing cardiovascular drug development, today […]
The addition of cardiology and neurology experts helps health companies scale evidence-based health products with confidence AUSTIN, Texas, Sept. 25, 2025 /PRNewswire/ — MDisrupt announced today that it is onboarding professional members of the American Heart Association® to its expert…
KIRKLAND, Wash., Sept. 25, 2025 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced its debut at the 2025 Heart Failure Society of America (HFSA) Annual Scientific Meeting, September 26–29 in Minneapolis, Minnesota. At booth #920, Kestra will feature its Cardiac Recovery System® (CRS) platform, anchored by the ASSURE® Wearable Cardioverter Defibrillator. The CRS platform closes the critical gap in sudden cardiac death protection by pairing protection with actionable insights that support confident care during the high-risk early phase of heart failure recovery. Attendees can explore the CRS platform through an immersive booth experience and hands-on demonstrations that highlight how it empowers clinicians, strengthens patient–provider connections, and supports recovery for vulnerable patients. “Our presence at HFSA underscores Kestra’s commitment to advancing care for heart failure patients,” said Brian Webster, President and Chief Executive Officer of Kestra Medical Technologies. “The Cardiac Recovery System platform redefines how sudden cardiac arrest risk is managed, equipping clinicians with technologies and insights that protect patients and strengthen recovery support.” Kestra will also participate in the Devices in Heart Failure Meeting on Friday, September 26, where attendees can see the ASSURE system up close and learn how it integrates into clinical workflows to support guideline-directed medical therapy. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, please visit www.kestramedical.com. CONTACT: Media contact
Rhiannon Pickus
rhiannon.pickus@kestramedical.com
Investor contact
Neil Bhalodkar
neil.bhalodkar@kestramedical.com
Cardiac Biotech Solutions, Inc. Secures Health Canada License for MyCardia AT Device, Now Branded as CardioHolter AT
DENVER–(BUSINESS WIRE)–Cleerly, a leader in AI-based cardiovascular imaging, today announced that Cigna will begin covering Cleerly LABS Advanced Plaque Analysis effective October 1, 2025. The coverage decision makes Cigna the latest major insurer to recognize the clinical and economic value of Artificial Intelligence Enabled CT Based Quantitative Coronary Tomography (AI-QCT)/Coronary […]
New global HQ features over 37,000 square feet that includes R&D and manufacturing BOSTON–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease, announced today the opening of its new global headquarters at 180 Third Avenue in Waltham, Mass. The new 37,811 […]
